More threads by Retired


Pharmacologic and Complementary Therapy for Migraine Prophylaxis
US Pharmacist
January 23, 2013

The revised guidelines developed by the AAN and the AHS for the use of pharmacologic agents and complementary therapies for migraine prophylaxis provide recommendations that were based on evidence-based clinical trials conducted after the release of the 2000 guidelines. This in-depth analysis gives an oversight of the methods, designs, and results of the clinical trials examining the efficacy of these agents. The updated guidelines address new therapies for the short-term prevention of MAM, namely, frovatriptan, naratriptan, and zolmitriptan. Also, new evidence in correlation with already established trial-based evidence supports the ineffectiveness of lamotrigine for migraine prophylaxis. Finally, the use of complementary therapies, such as herbal formulations, for migraine prophylaxis has been advanced by evidence-based efficacy in clinical trials, providing a new arsenal of evidence-based treatment during a time when the use of herbal formulations has become increasingly popular.

Because of formatting complexity a :acrobat: copy of the complete article is attached for download, review and/ or printing.


  • US Pharmacist migraine.pdf
    338.2 KB · Views: 3
Replying is not possible. This forum is only available as an archive.